CNTB
NASDAQ · Biotechnology
Connect Biopharma Holdings L
$0.70
+0.01 (+1.44%)
Financial Highlights (FY 2026)
Revenue
62.9K
Net Income
-57,021,356
Gross Margin
—
Profit Margin
-86,687.5%
Rev Growth
—
D/E Ratio
—
Revenue & Net Income
Margin Trends
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Gross Margin | — | 56.4% | 56.4% | 56.4% |
| Operating Margin | -90,740.6% | 6.4% | 7.1% | 6.5% |
| Profit Margin | -86,687.5% | 6.2% | 7.1% | 5.9% |
Income Statement
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Revenue | 62.9K | 69.44M | 70.73M | 65.75M |
| Gross Profit | — | 39.14M | 39.87M | 37.06M |
| Operating Income | -57,097,627 | 4.42M | 5.05M | 4.29M |
| Net Income | -57,021,356 | 4.31M | 5.04M | 3.90M |
| Gross Margin | — | 56.4% | 56.4% | 56.4% |
| Operating Margin | -90,740.6% | 6.4% | 7.1% | 6.5% |
| Profit Margin | -86,687.5% | 6.2% | 7.1% | 5.9% |
| Rev Growth | — | +2.8% | -4.7% | +21.9% |
Balance Sheet
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Total Debt | 0 | 72.52M | 64.29M | 59.58M |
| Total Equity | — | 80.64M | 74.11M | 84.59M |
| D/E Ratio | — | 0.90 | 0.87 | 0.70 |
Cash Flow
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| EBITDA | -58,960,585 | 5.85M | 6.49M | 5.56M |
| Free Cash Flow | — | 3.99M | 3.58M | 4.07M |